Indian Firms Push For Favorable USTR IPR Review

It’s that time of the year when Indian and US firms lock horns around all things IPR [intellectual property rights] ahead of the USTR’s annual Special 301 report. Indian pharma firms want India off the USTR’s Priority Watch List, while PhRMA says it remains concerned about the challenging policy environment and weak patent enforcement in India.

Pills world map
INDIAN FIRMS SAY THE IPR REGIME HAS IMPROVED IN THE COUNTRY

Frontline Indian pharmaceutical firms want the United States Trade Representative (USTR) to take India off the Priority Watch List in its annual Special 301 Report in view of the “strides” made towards an improved intellectual property rights (IPR) regime and to sustain this “forward momentum”.

These firms claim that “administrative improvements” in patent issuance and enforcement demonstrated in 2015 and 2016 have been sustained and...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet